Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmaceutical industry’s policy proposals set sights on non-communicable diseases

This article was originally published in Scrip

Executive Summary

Behind the scenes over the last ten years, the pharmaceutical industry has been going through some important changes in how it responds to the need for medicines and vaccines in developing countries. The AIDS epidemic in many developing countries was the tipping point and set the changes in motion. Now, the global health community faces a different, but just as challenging a task: to address the mounting threats of cardiovascular diseases, diabetes, cancers, and chronic respiratory diseases (collectively called “non-communicable diseases”, or NCDs). Today, the pharmaceutical industry is ready to respond to calls for action and will announce at the United Nations (UN) in New York a Framework for Action for the prevention and control of non-communicable diseases.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC013325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel